Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium bifidum Rosell-71
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum Rosell-71 (also known as R0071 or B. bifidum R71) is a probiotic strain developed and produced by Lallemand Health Solutions. Isolated from the human intestine and deposited at the Pasteur Institute (CNCM I-3426), it is a live biotherapeutic that interacts with the gut epithelium and modulates the host immune system. Specifically, it has been shown to reduce pro-inflammatory cytokine responses, including TNF and IL-10. Clinically, it is indicated for gastrointestinal health, such as stress-associated diarrhea, and respiratory health, including the reduction of cold-like symptoms in stressed adults. It is a primary component of the multi-strain pediatric formulation Probiokid® and holds regulatory approvals in Canada and China for specific health claims and use in infant food.
- Other names
- B. bifidum R71Bifidobacterium bifidum R71Bifidobacterium bifidum strain Rosell-71
02
Targets
IL10 (Interleukin-10)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Bifidobacterium bifidum Rosell-71.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium bifidum Rosell-71.